- Tarn SH, Sassoli PM, Jordan RE et al. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha (v)beta3 integrins. Circulation 1998; 98: 1085-1091.
- Jenkins LA, Lau S, Crawford M, Keung K. Delayed profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1998; 31: 1214-1215.
- Berkowitz SD, Sane DC, Sigmon KN et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the prevention of ischemic complications. EPIC study group. J Am Coll Cardiol 1998; 32: 311-319.
- Edward TA Fry MD. Readministration of abciximab in percutaneous coronary intervention. J Invas Cardiol 1999; 11: 251-258.
- Joseph T, Marco J, Gregorini L. Acute profound thrombocytopenia after abciximab therapy during coronary angioplasty. Clin Cardiol 1998; 11: 851-852.
- Jubelirer SJ, Koenig BA, Bates MC. Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: case reports, review of the literature and implications for therapy. Am J Hematol 1999; 61: 205-208.
- Bednar B, Bednar RA, Cook JJ et al. Drug-dependent anti-bodies against GP IIb/IIIa induced thrombocytopenia (abstr). Circulation 1996; 94(suppl I): 1-99.
- Berkowitz SD, Sane DC, Sigmon KN et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J Am CoIl Cardiol 1998; 32: 311-319.
- Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1-7.
- Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecularweight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
- Demasi R, Bode AP, Knupp C et al. Heparin-induced thrombocytopenia. Am Surg 1994; 60: 26-29.
- Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci 1993; 305: 208-215.
- Visentin GP, Ford SE, Scott JP et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-88.
- Amiral J, Bridey F, Dreyfus M et al. Platelet factor 4 complexed to heparin is target for antibodies generated in heparin-induced thrombocytopenia (letter). Thromb Haemost 1992; 68: 95-96.
- Kelton JG, Smith JW, Warkentin TE et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83: 3232-3239.
- Rebulla P, Finazzi G, Marangoni F et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo ltaliano Malattie Ematologiche Maligne dell Adulto. N Engl J Med 1997; 337: 1870-1875.
- Wandt H, Frank M, Ehninger G et al. Safety and cost effectiveness of 10×10(9)/L trigger for prophylactic platelet transfusions compared with traditional 20×10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998; 91: 3601-3606.
- Gil-Fernandez J, Alegre A, Fenandez-Villalta M et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant 1996; 18: 931-935.
- Sagmeister M, Oec E, Gmur J. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 1999; 93: 3124-3126.
- Harkness DR, Byrnes JJ, Lian E et al. Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA 1981; 246: 1931-1933.
- Lind SE. Thrombocytopenic purpura and platelet transfusions (letter). Ann Intern Med 1987; 106: 478.
- Burgess JK, Lopez JA, Berndt MC et al. Quinine-dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex: characterization of the epitopes. Blood 1998; 92: 2366-2373.
- Contre S. Heparin induced thrombocytopenia. UpToDate 2001; 9.1: 1-9. (see www.uptodate.com)
- Brieger DB, Mak KH, Kohke-Merchant K, Topol EJ. Heparin induced thrombocytopenia. J Am Coll Cardiol 1998; 31: 1449-1459.
- Warkentin TE, Sheppard JA, Horsewood P et al. Impact of the patient population on the risk of heparin induced thrombocytopenia. Blood 2000; 96: 1703-1708.
International Journal of Cardiovascular Interventions
Volume 4, 2001 - Issue 3